Idatha entsha yeKlinikhi eNtsha kwiZigulana ezineeCancer zeGastrointestinal

Ibhalwe ngu umhleli

I-Mirati Therapeutics, Inc., inkampani ye-oncology ejoliswe kwinqanaba lonyango, namhlanje ibhengeze iziphumo ezilungileyo ezivela kwiqela leSigaba se-2 sophononongo lwe-KRYSTAL-1 oluvavanya i-adagrasib kwidosi ye-BID ye-600mg kwizigulana ezine-pretreated pancreatic ductal adenocarcinoma kunye nezinye izimila zesisu (GI) Ukugcina uguquko lwe-KRASG12C, kubandakanya imihlaza yomgudu webiliary, i-appendix, amathumbu amancinci, i-gastro-esophageal junction, kunye nommizo. Iziphumo zibonise ukuba i-adagrasib ibonise umsebenzi obalulekileyo wekliniki kunye nolawulo olubanzi lwezifo.

Print Friendly, PDF & Email

Iziphumo (i-Abstract # 519) ziya kuboniswa namhlanje ngo-10: 00 am ET ngexesha leseshoni ekhawulezayo ye-abstract kwi-2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.      

UGqr. Tanios S. Bekaii-Saab, umphandi wophononongo lwe-KRYSTAL-1, uthe, “Ii-cancer zesisu zezinye zezona zixhaphakileyo ze-cancer kwaye ziyaqhubeka nokunxulunyaniswa neziphumo ezibi zokusinda nangona kukho inkqubela phambili yamva nje, ngakumbi kwizigulana ezine-GI tumors Utshintsho lwe-KRASG12C Idatha entsha yeklinikhi eboniswe kwi-ASCO GI ibonisa ukuba i-adagrasib, inhibitor ye-KRASG12C, ibonise umsebenzi othembisayo wekliniki kwizigulana ezinomhlaza we-pancreatic kunye namanye amathumba e-GI. Ezi ziphumo zakhela kwidatha yeklinikhi ye-adagrasib ebixelwe ngaphambili kwi-colorectal kunye ne-pancreatic cancers, kwaye iyakhuthaza kakhulu, iqinisekisa uphando olongezelelweyo lwe-adagrasib kwesi silungiselelo. "

Isishwankathelo seziphumo zoNyango

Ukusukela nge-10 kaSeptemba 2021, iseti esezantsi yezigulana ezine-GI zomhlaza ezigcina utshintsho lwe-KRASG12C ababhaliswe kwi-adagrasib monotherapy arm (n=30) bafumene ubuncinci imigca emibini yangaphambili yonyango lwenkqubo ye-anticancer, kwaye babenolandelelwano oluphakathi lweenyanga ezi-6.3 .

• Kwizigulane ezivandlakanywayo (n=27), izinga lempendulo yenjongo (ORR) yayingama-41% kwaye izinga lokulawula isifo (DCR) laliyi-100%. Kwizigulane ezivavanyayo ezinomhlaza we-pancreatic (n = 10), izinga lokuphendula (RR) laliyi-50%, kubandakanywa ne-1 engaqinisekanga impendulo engaphelelanga (PR); ubude bexesha lokuphendula (mDOR) ziinyanga ze-7.0, kunye nokulandelelaniswa kweenyanga ze-8.1. Kwizigulane ezinezinye izicubu ze-GI (n = 17), i-RR yayiyi-35%, kunye nee-PRs ezimbini ezingaqinisekanga; i-mDOR ibiziinyanga ezisi-7.9 kwezi zigulana, nolandelelwano oluphakathi lweenyanga ezi-6.3.

• I-median progression free survival (mPFS) kwizigulane ezinomdlavuza we-pancreatic ziinyanga ze-6.6 (i-95% ye-Confidence Interval, CI: 1.0, 9.7), kunye nezigulane ezinezinye ii-tumors ze-GI, i-mPFS yayiyi-7.9 iinyanga (95% CI 6.90-). 11.30).

• Kuluhlu olupheleleyo lwezigulane ezine-KRASG12C-mutated GI zomhlaza ezivavanyiweyo kweli qela, i-adagrasib inyamezeleke kakuhle, kunye neprofayili elawulekayo yokhuseleko. Iziganeko ezimbi ezinxulumene nonyango lweBakala 3/4 (TRAEs) zabonwa kwi-27% yezigulane eziphathwe nge-adagrasib, ngaphandle kwe-TRAEs ekhokelela ekuyekisweni konyango, kwaye akukho Grade 5 TRAEs ebonwayo.

"Sikholelwa ukuba i-adagrasib ineprofayili eyahlukileyo ye-molecular, kwaye idatha evezwe kwi-ASCO GI ixhasa ngakumbi iprofayili yayo engcono kakhulu eklasini," watsho uCharles M. Baum, MD, Ph.D., umsunguli, umongameli kunye nentloko yophando kunye uphuhliso, iMirati Therapeutics, Inc. “Iziphumo zibonise umsebenzi omhle wezonyango kwizigulana ezine-KRASG12C-mutated GI zomhlaza ezinyangwa nge-agent enye i-adagrasib, ngakumbi kwezo ezinomhlaza wepancreatic apho ukhetho lunqongopheleyo. Siyaqhubeka nokuvavanya ngokungqongqo i-adagrasib njengearhente enye kwaye ngokudibeneyo namanye amayeza omhlaza kwisicwangciso sophuhliso esibanzi sokunceda abantu abaninzi abaphila nomhlaza. "

Print Friendly, PDF & Email

Iindaba ezidibeneyo

Malunga nombhali

umhleli

Umhleli oyintloko we-eTurboNew nguLinda Hohnholz. Uzinze kwi-eTN HQ e-Honolulu, eHawaii.

Shiya Comment